['CONCOMITANT DRUG', 'EFFECT ON CONCENTRATION OF LAMOTRIGINE OR CONCOMITANT DRUG', 'CLINICAL COMMENT', 'ESTROGEN-CONTAINING ORAL CONTRACEPTIVE PREPARATION CONTAINING 30 MCG ETHINYLESTRADIOL AND 150 MCG LEVONORGESTREL', '\xe2\x86\x93 LAMOTRIGINE \xe2\x86\x93 LEVONORGESTREL', 'DECREASED LAMOTRIGINE LEVELS APPROXIMATELY 50%. \xc2\xa0\xc2\xa0DECREASE IN LEVONORGESTREL COMPONENT BY 19%.', 'CARBAMAZEPINE (CBZ) AND CBZ EPOXIDE', '\xe2\x86\x93 LAMOTRIGINE ? CBZ EPOXIDE', 'ADDITION OF CARBAMAZEPINE DECREASES LAMOTRIGINE CONCENTRATION APPROXIMATELY 40%. MAY INCREASE CBZ EPOXIDE LEVELS', 'PHENOBARBITAL/PRIMIDONE', '\xe2\x86\x93 LAMOTRIGINE', 'DECREASED LAMOTRIGINE CONCENTRATION APPROXIMATELY 40%.', 'PHENYTOIN (PHT)', '\xe2\x86\x93 LAMOTRIGINE', 'DECREASED LAMOTRIGINE CONCENTRATION APPROXIMATELY 40%.', 'RIFAMPIN', '\xe2\x86\x93 LAMOTRIGINE', 'DECREASED LAMOTRIGINE AUC APPROXIMATELY 40%.', 'VALPROATE', '\xe2\x86\x91 LAMOTRIGINE ? VALPROATE', 'INCREASED LAMOTRIGINE CONCENTRATIONS SLIGHTLY MORE THAN 2-FOLD. DECREASED VALPROATE CONCENTRATIONS AN AVERAGE OF 25% OVER A 3-WEEK PERIOD THEN STABILIZED IN HEALTHY VOLUNTEERS; NO CHANGE IN CONTROLLED CLINICAL TRIALS IN EPILEPSY PATIENTS.']